TBS 6

Drug Profile

TBS 6

Alternative Names: TBS-6

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trimel Pharmaceuticals Corporation
  • Developer Acerus Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Allergic rhinitis

Highest Development Phases

  • No development reported Allergic rhinitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Allergic-rhinitis in Canada (Intranasal, Spray)
  • 08 Sep 2015 Trimel Pharmaceuticals is now called Acerus Pharmaceuticals
  • 04 Mar 2015 Preclinical development is ongoing in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top